Johnson&Johnson
MedTech

Subject: **DePuy Synthes and Johnson & Johnson Legal Entity Separation Update**

11th September 2026

Dear Valued DePuy Synthes Customer,

On October 14, 2025, Johnson & Johnson (NYSE: JNJ) announced plans to separate its orthopaedics business, establishing DePuy Synthes as a standalone orthopaedics-focused company. This planned separation reflects the continued evolution of the healthcare industry and is intended to position both organizations with greater focus and flexibility to better serve customers, healthcare professionals, and patients. You can find more information related to the Separation, HERE.

As we separate DePuy Synthes from Johnson & Johnson's other healthcare businesses, we expect this to be seamless for our customers and their purchase experience and our goal is to maintain continuity for our customers. We do not expect any material changes to the commercial terms of our current agreements or our ordinary course of business following the Separation. In fact, the separation will enable DePuy Synthes to operate as one of the largest, most comprehensive orthopaedics-focused businesses. We are committed to transparency and will continue to share updates as more information becomes available.

Future communications will provide advance notice of any changes, if and when they occur. Though there are no immediate actions required, here's what you can do now:


- Identify key internal contacts (e.g., Accounts Payable, Vendor Master, Procurement, Contracting) who support supplier setup and contract administration.
- Watch for additional updates from us as details are finalised.
- Share this notice with other appropriate individuals within your organisation.

If you have questions in the meantime, please contact your DePuy Synthes representative or Customer Services:

- General Customer Services telephone: 0800 018 0118
- Loan bookings email: DSCSUKLOANS@ITS.JNJ.COM
- Sales orders email: DSCSUKORDERS@ITS.JNJ.COM

We are confident that this planned separation will allow DePuy Synthes to continue to be a strong, focused partner. Thank you for your continued partnership and trust.

Sincerely,



**Samantha Whiting**
General Manager DePuy Synthes UK